693248-53-2 Usage
Uses
Used in Organic Synthesis:
3-Oxabicyclo[3.1.0]hexane-6-carboxylic acid is used as a building block in the synthesis of more complex organic molecules. Its unique structure allows for the creation of a variety of compounds with diverse properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Oxabicyclo[3.1.0]hexane-6-carboxylic acid is used as a starting material for the development of new pharmaceuticals. Its structural features make it a promising candidate for the design of novel drugs with potential therapeutic effects.
Used as a Model Compound in Chemical Research:
3-Oxabicyclo[3.1.0]hexane-6-carboxylic acid is also used as a model compound for studying the reactivity and properties of bicyclic organic compounds. This helps researchers to better understand the behavior of similar compounds and to develop new synthetic methods and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 693248-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,3,2,4 and 8 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 693248-53:
(8*6)+(7*9)+(6*3)+(5*2)+(4*4)+(3*8)+(2*5)+(1*3)=192
192 % 10 = 2
So 693248-53-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H8O3/c7-6(8)5-3-1-9-2-4(3)5/h3-5H,1-2H2,(H,7,8)
693248-53-2Relevant articles and documents
TGF-betaR1 inhibitor and application thereof
-
Paragraph 0849; 0854-0856, (2020/06/09)
The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.
